Cargando…
Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer
[Image: see text] Anaplastic lymphoma kinase (ALK) rearrangements occur in about 5% of nonsmall cell lung cancer (NSCLC) patients. Despite being first recognized as EML4-ALK, fusions with several additional genes have been identified, all of which cause constitutive activation of the ALK kinase and...
Autores principales: | Balasundaram, Ambritha, C Doss, George Priya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666221/ https://www.ncbi.nlm.nih.gov/pubmed/38027370 http://dx.doi.org/10.1021/acsomega.3c05785 |
Ejemplares similares
-
Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (TP53) upon Hotspot Mutation p53 Arg248 by Comparative Computational Approach
por: Balasundaram, Ambritha, et al.
Publicado: (2022) -
Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase
por: Liang, Shuai, et al.
Publicado: (2021) -
TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
por: Ouseph, Madhu M, et al.
Publicado: (2019) -
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
por: Yang, Shuang, et al.
Publicado: (2023) -
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)